GSE122428 Gene expression changes induced by hypomethylating agent, Azacitidine (AZA) ; IDH1 inhibitor, BAY1436032 (BAY) and combination of BAY and AZA in sorted human (CD45+) cells from bone marrow of IDH1mut Patient derived Xenotransplantation mice model.

Contributors : Anuhar Chaturvedi ; Michael HeuserSeries Type : Expression profiling by arrayOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 months, suggesting that IDH1 inhibitors should be combined with other agents to improve efficacy. BAY 1436032 (BAY) is an oral pan-mutant IDH1 inhibitor currently undergoing phase 1 clinical trials. 5-Azacitidine (AZA) is a hypomethylating agent and can activate key epigenetically silenced pathways in AML cells, leading to an arrest of AML cell proliferation.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

Related Links:

CONCLUSION: Structural prevention measures in addition to behavioral measures enable a reduction of the cancer risk caused by UV radiation. The aim must be to establish these measures nationwide for the entire population. PMID: 32494842 [PubMed - as supplied by publisher]
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
This study sought to determine the incidence rates of all gynecologic, including peritoneal, malignancies in the U.S. Active Duty population compared to the general US population as reported in the Surveillance, Epidemiology, and End Results Program database. MATERIALS AND METHODS: Gynecologic cancers diagnosed in U.S. Active Duty women aged 20-59 between 2004 and 2013 were retrospectively ascertained. Cancer cases were identified in both the Automated Central Tumor Registry and the Military Health System Data Repository. All cases in Automated Central Tumor Registry plus cases recorded in Military Health System Data R...
Source: Military Medicine - Category: International Medicine & Public Health Tags: Mil Med Source Type: research
Publication date: Available online 5 June 2020Source: Gynecologic Oncology ReportsAuthor(s): Maryam Kasraeian, Kamran Hessami, Homeira Vafaei, Nasrin Asadi, Leila Foroughinia, Shohreh Roozmeh, Khadije Bazrfashan
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Publication date: Available online 4 June 2020Source: Gynecologic Oncology ReportsAuthor(s): María Jesús Rubio, María José Lecumberri, Silvia Varela, Jesús Alarcón, María Eugenia Ortega, Lydia Gaba, Jaime Espinós, Julia Calzas, Pilar Barretina, Isabel Ruiz, Gloria Marquina, Ana Santaballa
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
CONCLUSIONS: Our data provide new insights into the biology driving metastasis in PTCs and highlight how lncRNAs cooperate with coding transcripts to sustain these processes. PMID: 32495722 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
CONCLUSIONS: Fusion genes were the most common genetic cause of pediatric PTCs. Fusion gene positive PTCs showed more aggressive behavior than fusion gene negative PTCs. Several novel rearrangements were identified. Fusion genes seem to be a molecular marker number one in pediatric PTC patients. PMID: 32495721 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
LUNG CANCER symptoms include difficulty breathing, headaches, and persistent chest pain. But you could also be at risk of an advanced tumour if you develop a subtle sign on your eyes. Could you be at risk of lung cancer?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 4 June 2020Source: Annals of Medicine and SurgeryAuthor(s): Yasser El Ghamrini, Tamer M.S. Salama, Mohamed I. Hassan, Haytham Mohamed Nasser
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
Conclusion: Collectively, our results revealed that ruxolitinib may have therapeutic potential in glioblastomas, possibly by JAK/STAT signaling triggered by IFN-α and IFN-γ. PMID: 32492985 [PubMed - as supplied by publisher]
Source: Journal of Korean Neurosurgical Society - Category: Neurosurgery Tags: J Korean Neurosurg Soc Source Type: research
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 mont...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Brain Tumor | Cancer | Cancer & Oncology | Chondrosarcoma | Clinical Trials | Genetics | Glioma | Leukemia | Lymphoma | Melanoma | Oral Cancer | Skin Cancer | Thyroid | Thyroid Cancer